Navigation Links
Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281

- Results Reported at the American Diabetes Association Meeting Validate Mechanistic and Therapeutic Potential of sEH Inhibitor in Treating Type 2 Diabetes -

SOUTH SAN FRANCISCO, Calif., June 9 /PRNewswire/ -- Arete Therapeutics Inc. today announced the presentation of three posters that validate the mechanistic activity and therapeutic potential of the company's lead drug candidate, AR9281, an orally-administered soluble epoxide hydrolase (sEH) inhibitor that is in a Phase II clinical program for the treatment of type 2 diabetes. sEH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

Presented at the 69th Scientific Sessions of the American Diabetes Association (ADA) the data demonstrate that AR9281 exerts sEH mechanism-based improvement in glucose tolerance in preclinical models of type 2 diabetes. In addition, clinical data demonstrate a linear relationship between AR9281 exposure and blood sEH activity.

"Taken together, these data showing AR9281's safety and attractive pharmaceutic properties in normal healthy volunteers and strong evidence of its efficacy in animal models of type 2 diabetes support the further development of this novel drug candidate for the treatment of type 2 diabetes," said James A. Sabry, MD, PhD, Arete's President and Chief Executive Officer. "We anticipate that the results from our ongoing phase IIa clinical program in pre-diabetic patients will establish proof of concept that sEH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension to further corroborate the clinical importance of this novel therapeutic approach."

Three Posters Presented at ADA

The data presented by Arete scientists and colleagues are described as follows.

    -- "AR9281, a Soluble Epoxide Hydrolase Inhibitor - Efficacy in a DIO
       Mouse Model plus Pharmacokinetics and Pharmacodynamics in Mice and Men"
       (Whitcomb, R, Chen, D, Wang, J, Anandan, S-K, Gless, R and Webb, H).

       This poster describes the direct correlation between the concentration
       of AR9281 in blood and the activity of its target, sEH, in both mice
       and humans. The data further demonstrate that AR9281 improves glucose
       metabolism in rodent models of type 2 diabetes.

    -- "A Novel Inhibitor of Soluble Epoxide Hydrolase, AR9281, Improves
       Glucose Homeostasis in Diet-Induced Obese Mice" (Wong, K, Zhang, L-N,
       Vincelette, J, Chen, D, Mehra, U, Cheng, Y, Gless, R, Anandan, S-K,
       Webb, H).

       Data presented in this poster show that in diet-induced obese mice,
       AR9281 inhibits sEH and improves glucose tolerance in a highly-dose
       dependent manner. Improvement of glucose tolerance by AR9281 is not
       observed in sEH knock-out mice indicating that the action of AR9281 is
       sEH mechanism-based.  These positive effects are associated with
       reductions in plasma insulin, IL-6, an inflammatory molecule elevated
       in people with type 2 diabetes, and resistin, a hormone that plays a
       role in predisposing obese individuals to diabetes.

    -- "Improvement of Glucose Homeostasis by AR9281, a Novel Inhibitor of
       Soluble Epoxide Hydrolase, in Diet-Induced Obese Mice Does Not Depend
       on Active Nitric Oxide Synthase" (Vincelette, J, Chen, D, Mehra, U,
       Cheng, Y, Gless, R, Anandan, S-K, MacIntyre, E and Wang, J).

       Data presented in this poster show the correlation between treatment
       with AR9281 and the lowering of the glucose levels after an oral
       glucose tolerance test and demonstrate that these effects are not
       inhibited by concurrent treatment with the nitric oxide synthase
       inhibitor L-NAME (NG-nitro-L-arginine methyl ester), thus furthering
       the understanding of the mechanism of action of this novel drug

AR9281 Phase II Program Underway

Arete is conducting a Phase IIa multicenter, double-blind, placebo-controlled study of AR9281 in pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All 150 enrolled patients will be treatment-naive for type 2 diabetes medications. The trial is evaluating two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient receives 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.

The Phase I clinical program for AR9281, consisting of two double-blind, placebo-controlled studies, demonstrated that AR9281 was safe and well tolerated in healthy volunteers. The studies met all safety, tolerability, pharmacokinetic and pharmacodynamic endpoints. In addition, AR9281 has shown favorable results in various published and proprietary in vitro and in vivo assays for potency, selectivity, efficacy, ADME, toxicity and safety.

About AR9281

AR9281, an orally-administered soluble epoxide hydrolase (sEH) inhibitor, operates within the third branch of the arachidonic acid pathway and represents a novel and potentially more effective approach to treating type 2 diabetes, hypertension and inflammatory disease. The first two branches of this critical regulatory pathway have been targeted by several commercially successful marketed anti-inflammatory drugs including Aspirin(R) (acetylsalicylic acid), Motrin(R) (ibuprofen), Singulair(R) (montelukast) and Celebrex(R) (celecoxib). AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens.

About Arete Therapeutics Inc.

Arete Therapeutics is a privately-held biotechnology company dedicated to the discovery and development of novel drugs to treat type 2 diabetes, hypertension and inflammatory disorders. It is the world's leading company focused on sEH, an important enzyme for the metabolism of arachidonic acid that plays an essential role in metabolic, inflammatory and cardiovascular physiology. The Company has raised a total of over $51 million in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three Arch Partners, Burrill & Company and Altitude Life Science Ventures. For more information on Arete Therapeutics, please visit

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.


SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CareTech Receives National Recognition in 2009 Aster Awards for Medical Marketing Excellence
2. CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals
3. CareTech Solutions Caps Banner Year by Signing Pennsylvanias Lehigh Valley Health Network, Tennessees Covenant Health, and Ohios Marietta Memorial Hospital to Provide Web Services
4. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
5. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
8. CareTech Solutions Service Desk Equals Help Desk Plus
9. Arete Therapeutics Appoints Donald Santel to Board of Directors
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic ... list of CAAHEP accredited colleges, as only one of twelve colleges and universities in ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... ... 26, 2015 , ... WorldCare International, Inc., the first company ... Employee Benefits Conference. The Employee Benefits Conference was hosted by the International Foundation ... 11th, 2015. The conference was held at the Hawaii Convention Center in Honolulu, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... global healthcare industry is expected to grow at a rate ... has the highest projected growth at 12.7%, and ... is second with growth projected at 11.5%. ... 2013-2014, total government funded healthcare was nearly 68%. Federal government ... 2013-2014. In real terms, out of pocket expenditure increased by ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: